Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis

• Post author:
• Post published:June 24, 2026
• Post category:

Amyotrophic lateral sclerosis (ALS), a lethal disease lacking effective treatments, is characterized by the loss of upper and lower motor neurons. 5-10% of ALS is familial, but the majority of…

Continue ReadingStem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis

Identification and characterization of human ES-derived DA neuronal subtypes

• Post author:
• Post published:June 24, 2026
• Post category:

Parkinson’s disease (PD) is a neurodegenerative movement disorder that affects 1 in 100 people over the age of 60, one million people in the US and six million worldwide. Patients…

Continue ReadingIdentification and characterization of human ES-derived DA neuronal subtypes

Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons

• Post author:
• Post published:June 24, 2026
• Post category:

One of the main objectives of stem cell biology is to create physiologically relevant cell types that can be used to either facilitate the study of or directly treat human…

Continue ReadingMolecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons

Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingPersonalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A

A Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingA Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach

Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingLate-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

Microglia replacement therapy for CSF1R-related Leukoencephalopathy

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingMicroglia replacement therapy for CSF1R-related Leukoencephalopathy

CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingCRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia

Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingDevelopment of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders

Dissecting cell-specific genetic and molecular drivers of amyotrophic lateral sclerosis for therapeutic insights

• Post author:
• Post published:June 23, 2026
• Post category:

Continue ReadingDissecting cell-specific genetic and molecular drivers of amyotrophic lateral sclerosis for therapeutic insights